Neurological Complications of Systemic Cancer and Antineoplastic Therapy

Neurological Complications of Systemic Cancer and Antineoplastic Therapy

2nd Edition - March 15, 2022

Write a review

  • Editors: Herbert B. Newton, Mark G. Malkin

Purchase options

No purchase options available.

Institutional Subscription

Free Global Shipping
No minimum order

Description

Neurological Complications of Systematic Cancer and Antineoplastic Therapy, Second Edition provides an expanded, updated and in-depth review of common manifestations related to neurology that occur in patients with systemic cancer. These include brain metastases, spinal cord compression, cerebrovascular events, and leptomeningeal disease. The book also discusses neurological complications related to treatments such as radiation and chemotherapy and is an essential reference for the practicing neurologist and oncologist. Sections in this new release cover the pathophysiology and molecular biology of cancer and the metastatic phenotype, Metastatic spread to cranial and peripheral nerves and brachial and lumbosacral plexuses, Metabolic and nutritional disorders, CNS infections, Neurological complications of immunotherapy and bone marrow transplants, Neurological complications of new molecular agents and immuno-modulatory drugs, and more.

Key Features

  • Summarizes the neurologic effects of both cancer and cancer treatment
  • Provides scientific and clinical information relevant to research and treatment
  • Identifies neurological complications by tumor type and tumor therapy
  • Covers GI, lung, breast, gynecological, head and neck cancers, and more
  • Includes radiotherapy, chemotherapy, immunotherapy, and new drugs
  • Contains melanoma, lymphoma, sarcoma, myeloma, leukemia, and more

Readership

Graduate students in biological and biomedical sciences, neuroscientists, clinicians (especially neurosurgery, neurology and neuroradiology), oncologists, cancer researchers, pharmaceutical scientists, biomedical scientists, post-doctoral fellows, researchers with an interest in neuroimaging and neuro-oncology

Table of Contents

  • Cover image
  • Title page
  • Table of Contents
  • Copyright
  • Dedication
  • Contributors
  • About the editors
  • Preface
  • Section I: Metastatic neurological complications
  • Chapter 1: Common symptoms at presentation of nervous system metastases
  • Abstract
  • 1: Introduction
  • 2: Brain metastases
  • 3: Leptomeningeal disease
  • 4: Spinal cord metastases
  • 5: Epidural spinal cord metastases/epidural spinal cord compression
  • 6: Cauda equina syndrome
  • 7: Neoplastic and radiation plexopathy
  • 8: Conclusion
  • References
  • Chapter 2: Neuroimaging of systemic metastatic disease
  • Abstract
  • Acknowledgment
  • 1: Technical considerations
  • 2: Anatomic locations
  • 3: Intracranial complications of systemic disease
  • References
  • Chapter 3: Nonimaging evaluation of patients with nervous system metastases
  • Abstract
  • Disclosures
  • 1: Introduction
  • 2: Electroencephalography
  • 3: Evoked potentials
  • 4: Electromyography and nerve conduction studies
  • 5: Nerve biopsy
  • 6: Cerebrospinal fluid
  • 7: Conclusion
  • References
  • Chapter 4: Biology and pathophysiology of central nervous system metastases
  • Abstract
  • 1: Introduction
  • 2: Molecular biology of neoplasms
  • 3: Mechanisms of brain metastasis
  • 4: Biological mechanisms of the metastatic cascade
  • 5: Blood–brain barrier
  • 6: Genetics of metastases
  • 7: Conclusion
  • Disclosure
  • References
  • Chapter 5: Intracranial metastases
  • Abstract
  • 1: Introduction and epidemiology
  • 2: Pathology
  • 3: Clinical presentation
  • 4: Neuroimaging
  • 5: Surgical therapy
  • 6: Radiation therapy
  • 7: Chemotherapy
  • References
  • Further reading
  • Chapter 6: Neurosurgical approaches to the treatment of intracranial metastases
  • Abstract
  • 1: Background
  • 2: Initial approach
  • 3: Tumor resection
  • 4: Surgical adjuncts
  • 5: Other neurosurgical techniques
  • 6: Management of recurrence—When to repeat resection
  • 7: Management of CNS metastases in uncommon locations
  • 8: Conclusion
  • Disclosures
  • References
  • Chapter 7: Epidural metastasis and spinal cord compression
  • Abstract
  • 1: Introduction
  • 2: Epidemiology
  • 3: Pathophysiology
  • 4: Clinical presentation
  • 5: Diagnosis
  • 6: Prognosis
  • 7: Treatment
  • 8: Conclusion
  • References
  • Chapter 8: Leptomeningeal metastasis
  • Abstract
  • 1: Introduction
  • 2: Prognosis
  • 3: Anatomy
  • 4: Pathogenesis
  • 5: Clinical presentation
  • 6: Diagnostic studies/staging
  • 7: Treatment
  • 8: Summary
  • References
  • Chapter 9: Cranial nerve involvement by metastatic cancer
  • Abstract
  • 1: Introduction
  • 2: Clinical presentation of cranial nerve involvement
  • 3: Typical imaging findings of cranial nerve involvement
  • 4: Cancers of special interest
  • 5: Summary
  • References
  • Chapter 10: Cancer-related plexopathies
  • Abstract
  • 1: Introduction
  • 2: Review of plexus anatomy
  • 3: Plexopathy
  • 4: Diagnosis of plexopathy in patients with cancer
  • 5: Diagnostic studies
  • 6: Cancers of special interest
  • 7: Supportive treatment of cancer-related plexopathy
  • 8: Summary
  • References
  • Section II: Nonmetastatic neurological complications
  • Chapter 11: Cerebrovascular complications of malignancy
  • Abstract
  • 1: Epidemiology of cerebrovascular disease in malignancy
  • 2: Direct tumor effects and intracranial hemorrhage
  • 3: Direct tumor effects and cerebral infarction
  • 4: Coagulation disorders
  • 5: Cancer-related infectious disease and stroke: Septic cerebral infarction
  • 6: Infectious vasculitis
  • 7: Complications of cancer treatment
  • 8: Conclusion
  • References
  • Chapter 12: Metabolic and nutritional nervous system dysfunction in cancer patients
  • Abstract
  • 1: Introduction
  • 2: Metabolic and toxic encephalopathy
  • 3: Tumor lysis syndrome
  • 4: Cancer anorexia-cachexia syndrome
  • 5: Nutritional myelopathy
  • 6: Peripheral neuropathy
  • 7: Nutritional and toxic myopathy
  • 8: Immunotherapy side effects
  • 9: CAR-T cell complications
  • References
  • Chapter 13: Central nervous system infections in cancer patients
  • Abstract
  • 1: Introduction
  • 2: Approach to cancer patients with suspected CNS infection
  • 3: High-risk patient groups
  • 4: Management of common CNS infections
  • 5: Vaccine-preventable infections: The COVID-19 pandemic and cancer patients
  • 6: Conclusions
  • References
  • Chapter 14: Diagnosis and treatment of paraneoplastic neurological disorders
  • Abstract
  • 1: Introduction
  • 2: Pathogenesis
  • 3: Clinical diagnosis
  • 4: Antineuronal antibodies
  • 5: Treatment
  • 6: Underlying malignancy
  • 7: Paraneoplastic disorders and immune checkpoint inhibitors
  • 8: Paraneoplastic neurological disorders
  • 9: Conclusion
  • References
  • Section III: Neurological complications of specific neoplasms
  • Chapter 15: Neurological complications of lung cancer
  • Abstract
  • 1: Introduction
  • 2: Direct complications of lung cancer
  • 3: Indirect complications of lung cancer
  • References
  • Chapter 16: Neurological complications of breast cancer
  • Abstract
  • 1: Introduction
  • 2: Metastatic complications
  • 3: Nonmetastatic complications
  • 4: Regional approach to the diagnosis of neurological symptoms
  • 5: Conclusion
  • References
  • Chapter 17: Neurological complications of melanoma
  • Abstract
  • 1: Introduction
  • 2: Neurological complications of malignant melanoma
  • 3: Neurological complications of noncutaneous melanomas
  • References
  • Chapter 18: Neurological complications of lymphoma
  • Abstract
  • 1: Introduction
  • 2: Intracranial metastases
  • 3: Spinal cord processes
  • 4: Peripheral nervous system disease
  • 5: Paraneoplastic neurological syndromes
  • References
  • Chapter 19: Neurologic complications of the leukemias
  • Abstract
  • 1: Introduction
  • 2: Diagnostic considerations
  • 3: The acute leukemias
  • 4: The chronic leukemias
  • 5: Conclusion
  • References
  • Chapter 20: Neurological complications of systemic cancer of the head and neck
  • Abstract
  • 1: Introduction
  • 2: Local and locoregional complications
  • 3: Distant metastases
  • 4: Leptomeningeal carcinomatosis
  • 5: Medical therapy
  • 6: Syncope in patients with head and neck cancer
  • References
  • Further reading
  • Chapter 21: Neurological complications of gynecological cancers
  • Abstract
  • 1: Introduction
  • 2: Local/regional spread of gynecological cancers to the lumbosacral plexus
  • 3: Distant CNS metastases from gynecological cancers
  • 4: Paraneoplastic syndromes due to gynecological cancers
  • 5: Neurological complications associated with treatment of gynecological cancers
  • 6: Conclusion
  • References
  • Chapter 22: Neurological complications of GI cancers
  • Abstract
  • Permissions summary
  • 1: Overview of gastrointestinal cancers
  • 2: Neurological complications of GI cancers
  • 3: Common systemic treatment regimens for GI cancers and their neurological complications
  • References
  • Chapter 23: Neurologic complications associated with genitourinary cancer
  • Abstract
  • 1: Introduction
  • 2: Prostate cancer
  • 3: Uterus
  • 4: Ovarian cancer
  • 5: Renal carcinoma
  • 6: Germ cell testicular cancer
  • 7: Bladder carcinoma
  • 8: Conclusion
  • References
  • Chapter 24: Sarcoma and the nervous system
  • Abstract
  • 1: Introduction
  • 2: Primary CNS sarcomas
  • 3: Primary sarcomas of the peripheral nervous system
  • 4: Extra-CNS sarcoma affecting the nervous system
  • 5: CNS metastases from extra-CNS sarcoma
  • 6: Neurologic toxicities from sarcoma treatments
  • 7: Conclusions
  • References
  • Chapter 25: Neurological complications of multiple myeloma
  • Abstract
  • 1: Introduction
  • 2: Central nervous system complications
  • 3: Peripheral nervous system complications
  • 4: Conclusion
  • References
  • Chapter 26: Neurologic complications in the treatment of childhood malignancies
  • Abstract
  • 1: Introduction
  • 2: Part I: Acute complications of cancer treatment
  • 3: Part II: Late effects of cancer treatment
  • 4: Conclusion
  • References
  • Section IV: Neurological complications of antineoplastic therapy
  • Chapter 27: Neurological complications of radiation therapy
  • Abstract
  • 1: Introduction
  • 2: Pathophysiology of neurological complications from radiation
  • 3: Radiation-induced brain toxicity
  • 4: Radiation-induced complications of spinal cord
  • 5: Radiation-induced nerve injury
  • 6: Endocrinopathy after radiation therapy
  • 7: Cerebrovascular complications after radiation treatment
  • 8: Radiation-induced secondary malignancy
  • 9: Conclusion
  • References
  • Chapter 28: Neurological complications of systemic cancer and antineoplastic therapy
  • Abstract
  • 1: Introduction
  • 2: Mechanisms of neurotoxicity
  • 3: Neurotixicity of specific agents
  • 4: Targeted therapies
  • 5: Biological agents
  • 6: Chemotherapy-induced cognitive impairment
  • 7: Conclusion
  • References
  • Chapter 29: Neurological complications of hematopoietic stem cell transplantation
  • Abstract
  • 1: Introduction
  • 2: Neurologic complications associated with conditioning regimens
  • 3: Toxic-metabolic encephalopathy
  • 4: Cerebrovascular complications
  • 5: CNS infections
  • 6: Neurologic complications associated with chronic graft versus host disease (GVHD)
  • 7: Neurologic complications associated with immunosuppressive therapy
  • 8: Neurocognitive dysfunction
  • 9: Secondary malignancies
  • 10: Conclusion
  • References
  • Chapter 30: Chemotherapy-induced peripheral neuropathy
  • Abstract
  • 1: Introduction
  • 2: Pathophysiology of CIPN
  • 3: Clinical presentation and diagnostic evaluation of CIPN
  • 4: Clinical management of CIPN
  • References
  • Chapter 31: Neurological complications of immunotherapy and monoclonal antibody therapy
  • Abstract
  • 1: Introduction
  • 2: Bevacizumab
  • 3: Cetuximab and other anti-EGFR mAbs
  • 4: Trastuzumab
  • 5: Rituximab and other anti-CD20 mAbs
  • 6: Dinutuximab
  • 7: Brentuximab vedotin
  • 8: Polatuzumab vedotin
  • 9: Enfortumab vedotin
  • 10: Trastuzumab emtansine
  • 11: Blinatumomab
  • 12: Interleukin-2 (IL2)
  • 13: Interferon alpha
  • References
  • Chapter 32: Neurologic complications of immune modulatory therapy
  • Abstract
  • 1: Introduction
  • 2: Epidemiology
  • 3: Headache
  • 4: Malignant cerebral edema
  • 5: Peripheral nervous system
  • 6: Central nervous system
  • 7: CAR T cell-mediated neurotoxicity (immune effector cell-associated neurotoxicity syndrome)
  • 8: Conclusion: Diverse presentation, kinetics, importance of multidisciplinary and early treatment, consideration of re-challenge
  • References
  • Chapter 33: Neurological complications of steroids and of supportive care
  • Abstract
  • Acknowledgment
  • 1: Introduction
  • 2: Corticosteroids
  • 3: Seizures
  • 4: Vascular complications
  • 5: Analgesics
  • 6: Antiemetics
  • 7: Depression
  • 8: Summary
  • References
  • Section V: Psychiatric, pain, psychosocial, and supportive care issues
  • Chapter 34: Psychiatric aspects of care in the cancer patient
  • Abstract
  • 1: Introduction
  • 2: Historical background
  • 3: Common psychological responses to cancer
  • 4: Epidemiology of psychiatric disorders in cancer patients
  • 5: General principles of psychiatric assessment and treatment in patients with cancer
  • 6: Delirium
  • 7: Adjustment disorders
  • 8: Anxiety disorders
  • 9: Trauma and stressor-related disorders
  • 10: Depressive disorders
  • 11: Suicide assessment and management in cancer patients
  • 12: Psychiatric considerations in cancer-related fatigue
  • 13: Cancer survivors
  • 14: Families issues and bereavement
  • 15: Psychological issues for staff
  • References
  • Chapter 35: Chronic cancer pain syndromes and their treatment
  • Abstract
  • 1: Bone pain
  • 2: Pain syndromes of the viscera and miscellaneous tumor-related syndromes
  • 3: Headache and facial pain
  • 4: Neuropathic pain involving the peripheral nervous system
  • 5: Paraneoplastic nociceptive pain syndromes
  • 6: Chronic pain syndromes associated with cancer therapy
  • 7: Clinical evaluation of the patients with difficult pain
  • References
  • Further reading
  • Chapter 36: Psychosocial issues in cancer patients with neurological complications
  • Abstract
  • 1: Introduction
  • 2: Neurocognitive concerns
  • 3: Psychological concerns
  • 4: Behavioral concerns
  • 5: Social concerns
  • 6: Disparity concerns
  • 7: End-of-life concerns
  • 8: Conclusion
  • References
  • Chapter 37: Supportive care
  • Abstract
  • 1: Introduction
  • 2: Novel antiangiogenic agents
  • 3: Conclusion
  • References
  • Index

Product details

  • No. of pages: 678
  • Language: English
  • Copyright: © Academic Press 2022
  • Published: March 15, 2022
  • Imprint: Academic Press

About the Editors

Herbert B. Newton

Herbert B. Newton
Dr. Newton is currently the Director of the Neuro-Oncology Center and CNS Oncology Program at the Advent Health Cancer Institute and Advent Health Orlando Campus. He recently retired as Professor of Neurology and Neurosurgery at the Ohio State University Medical Center and the James Cancer Hospital, and was the holder of the Esther Dardinger Endowed Chair in Neuro-Oncology. He trained in Neuro-Oncology with Drs. Jerome Posner and William Shapiro at Memorial Sloan-Kettering Cancer Center in New York, and since then had been in academic Neuro-Oncology for over 25 years. He has published more than 220 peer-reviewed articles and book chapters, and is the Chief Editor or Co-Editor of ten textbooks in the field of Neurology and Neuro-Oncology. In addition, he has been listed as a Best Doctor (Neurology) and Top Doctor for Cancer (Neuro-Oncology) for the past 18 years.

Affiliations and Expertise

Director, Neuro-Oncology Center, Medical Director, CNS Oncology Program, Advent Health Cancer Institute, Advent Health Orlando, Campus & Advent Health Medical Group, Professor of Neurology, UCF School of Medicine, Orlando, FL, USA

Mark G. Malkin

Dr. Malkin is currently the Director of the Neuro-Oncology Program at Massey Cancer Center, and Director of the Neuro-Oncology Division, in the Department of Neurology at Virginia Commonwealth University School of Medicine. He holds the William G. Reynolds, Jr. Chair in Neuro-Oncology and is Professor of Neurology. Before his appointment at VCU, he was the Director of Neuro-Oncology and Professor of Neurology at Froedtert and the Medical College of Wisconsin. Prior to his move to Milwaukee, he was an Associate Clinical Member at Memorial Sloan-Kettering Cancer Center and Associate Clinical Professor of Neurology at Weill Cornell Medical College. He also trained in Neuro-Oncology with Drs. Jerome Posner and William Shapiro at Memorial Sloan-Kettering Cancer Center, and since then has been in academic Neuro-Oncology for over 33 years. He has published more than 100 peer-reviewed articles and book chapters and is Co-Editor of several textbooks in the field of Neuro-Oncology.

Affiliations and Expertise

Director of the Neuro-Oncology Program at Massey Cancer Center; Director of the Neuro-Oncology Division, Department of Neurology, Professor of Neurology and Neurosurgery, William G. Reynolds, Jr. Chair in Neuro-Oncology, Virginia Commonwealth University School of Medicine, Richmond, VA, United States

Ratings and Reviews

Write a review

There are currently no reviews for "Neurological Complications of Systemic Cancer and Antineoplastic Therapy"